Impact of granulocyte colony‐stimulating factor (CSF) and granulocyte–macrophage CSF in patients with malignant lymphoma: a systematic review

British Journal of Haematology - Tập 122 Số 3 - Trang 413-423 - 2003
Julia Bohlius1, Marcel Reiser, Guido Schwarzer, Andreas Engert
1Department of Internal Medicine I, University of Cologne, Germany. [email protected]

Tóm tắt

Summary. The granulopoiesis‐stimulating factors, granulocyte colony‐stimulating factor (G‐CSF) and granulocyte–macrophage colony‐stimulating factor (GM‐CSF), are used to prevent neutropenia and febrile neutropenia in patients with malignant lymphoma. The question as to whether G‐CSF/GM‐CSF improves dose‐intensity, tumour response and overall survival (OS) has not yet been answered. As the results from single studies are inconclusive, a systematic review was performed to determine the effectiveness of G‐CSF/GM‐CSF. Randomized controlled trials comparing prophylaxis with G‐CSF/GM‐CSF versus no prophylaxis in adult patients with malignant lymphoma undergoing conventional chemotherapy were included. Medical databases (Cochrane Library, Medline, Embase) and conference proceedings were searched. All authors were contacted to obtain missing data. We included 11 studies making a total of 1434 patients. Compared with no prophylaxis, G‐CSF/GM‐CSF significantly reduced the relative risk (RR) for neutropenia {RR 0·64 [95% confidence interval (CI) 0·55–0·75]} febrile neutropenia (RR 0·74 [95% CI 0·62–0·89]) and infection (RR 0·74 [95% CI 0·64–0·85]). G‐CSF/GM‐CSF did not decrease infection‐related mortality (RR 2·07 [95% CI 0·81–5·34]), improve complete remission (CR) (RR 1·06 [95% CI 0·96–1·16]) or OS (HR 0·98 [95% CI 0·81–1·18]). In conclusion, G‐CSF/GM‐CSF given during conventional chemotherapy in malignant lymphoma patients reduced the RR of neutropenia, febrile neutropenia and infection. However, there is no evidence that G‐CSF/GM‐CSF improved CR and OS in this clinical setting.

Từ khóa


Tài liệu tham khảo

10.1002/(SICI)1097-0142(20000115)88:2<454::AID-CNCR28>3.0.CO;2-Q

10.1056/NEJM199304083281409

10.3109/10428199409051691

Barbui T., 1996, Thrombosis in cancer patients treated with hematopoietic growth factors ‐ a meta‐analysis. On behalf of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee of the ISTH, Thrombosis and Haemostasis, 75, 368, 10.1055/s-0038-1650276

Bastion Y., 1993, A randomized double‐blind phase III study of Filgrastim (recombinant human G‐CSF) vs placebo during intensive induction chemotherapy in 55–69‐year old patients (pts) with poor prognosis aggressive Non‐Hodgkin's Lymphoma, Blood, 82, 143a

10.3109/07357909809115775

Björkholm M., 1999, Randomized trial of r‐met‐Hu granulocyte colony‐stimulating factor (G‐CSF) as adjunct to CHOP or CNOP treatment of elderly patients with aggressive Non‐Hodgkin's Lymphoma, Blood, 94, 599a

10.7326/0003-4819-64-2-328

Bohlius J. Reiser M. Schwarzer G.&Engert A.(2002)Granulopoiesis‐stimulating factors in the prevention of adverse effects in the chemotherapeutic treatment of malignant lymphoma. In:The Cochrane Library Issue 4 2002.

10.1038/bjc.1988.163

Diehl V., 2000, Dose escalated BEACOPP chemotherapy improves failure free survival in advanced Hodgkin's Disease: updated results of the German Hodgkin's Lymphoma Study Group, Blood, 96, 576a

Doorduijn J.K., 2000, Randomized trial of granulocyte‐colony stimulating factor (G‐CSF) added to CHOP in elderly patients with aggressive non‐Hodgkin's lymphoma (NHL), Blood, 96, 133a

10.1016/S0936-6555(05)80490-X

10.1136/bmj.315.7109.629

10.1093/annonc/5.suppl_2.S123

10.1007/s002770050330

10.1182/blood.V82.8.2329.2329

Gerhartz H.H., 1994, Recombinant human granulocyte‐macrophage colony‐stimulating factor as adjunct to chemotherapy in aggressive non‐Hodgkin's lymphomas, Seminars in Oncology, 21, 25

10.3109/10428199709114168

Goldie J.H., 1983, Quantitative model for multiple levels of drug resistance in clinical tumors, Cancer Treatment Report, 67, 923

10.1159/000227575

Gregory S., 1998, Fludarabine (F), Cyclophosphamide (C), and GM‐CSF (FCGM) is effective in chronic lymphatic leukemia (CLL) and low grade non Hodgkins lymphoma (LGNHL), Blood, 92, 276b

10.1200/JCO.1984.2.11.1281

10.1093/oxfordjournals.annonc.a058619

Liberati A.M., 1991, GM‐CSF: clinical trials in non‐Hodgkin's lymphoma patients with chemotherapy induced leucopenia, Leukemia, 5, 119

10.1172/JCI112705

Lyman G.H. Kuderer N.M.&Djulbegovic B.(2002)Prophylactic granulocyte colony‐stimulating factor in patients receiving dose‐intensive cancer.American Journal of Medicine 112 406–411.

10.1200/JCO.1996.14.3.925

10.1200/JCO.2000.18.20.3558

10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8

10.1182/blood.V80.6.1430.1430

Pettengell R., 1993, Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non‐Hodgkin's lymphoma, Blood, 82, 2239, 10.1182/blood.V82.7.2239.2239

Pfreundschuh M., 2001, 2‐weekly CHOP (CHOP‐14): the new standard for patients with aggressive Non Hodgkin's lymphoma (NHL) > 60 years of age, Blood, 98, #3027

Rusthoven J., 1998, Use of granulocyte colony‐stimulating factor (G‐CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group, Cancer Prevention and Control, 2, 179

Skipper H.E.(1990)Dose intensity versus total dose of chemotherapy: an experimental basis. In:Important Advances in Oncology(ed. by V. DeVita Jr S. Hellman & S.A. Rosenberg) pp.43–64. J.B. Lippincott Company Philadelphia.

10.2165/00019053-199400062-00007

Sweetenham J.W., 2000, Evidence‐based review and meta‐analysis of the use of hematopoietic growth factors (HGF) in the management of malignant lymphoma (ML), Blood, 96, 139a

10.1200/JCO.1995.13.3.652

10.1002/(SICI)1096-8652(199604)51:4<289::AID-AJH7>3.0.CO;2-S

Zinzani P.L., 1997, Randomized trial with or without granulocyte colony‐stimulating factor as adjunct to induction VNCOP‐B treatment of elderly high‐grade non‐ Hodgkin's lymphoma, Blood, 89, 3974

Zinzani P.L., 1999, Elderly aggressive‐histology non‐Hodgkin's lymphoma: first‐line VNCOP‐B regimen experience on 350 patients, Blood, 94, 33

Thông tin
Thông tin xuất bản

British Journal of Haematology

Tập 122 Số 3

413-423

Thông tin tác giả